Minimize
 

RTOG 0324 Protocol Information

Minimize
A Phase II Study of Cetuximab (C225) In Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Protocol Documents
Current Version Date: 5/6/2010
Principal Investigator: George Blumenschein, M.D.
Primary Objective:

Determine the feasibility of concurrent cetuximab and chemoradiation as measured by safety and compliance. Safety is measured by the rate of grade 3 or worse nonhematological toxicities occurring prior to the beginning of consolidation therapy (including

Patient Population:

Histologically or cytologically documented NSCLC; Patients must be MO. Patients with T1-T2 with N2 or T3N1-2 are eligible, if inoperable. Patients withT4 with any N or any T with N2 or N3 disease are eligible if unresectable.

Target Accrual: 84
Current Accrual: 93
Status: Terminated
Date: 11/5/2013
Participating Sites:
Genesys Regional Medical Center Flint MI
Hematology-Oncology Associates of CNY CCOP East Syracuse NY
Hurley Cancer Center Flint MI
Mercy Hospital Port Huron Port Huron MI
Methodist Cancer Center Omaha NE
Michigan Cancer Research Consortium CCOP Ann Arbor MI
Oakwood Healthcare Inc Dearborn MI
Saint Alphonsus Regional Medical Center Boise ID
Sparrow Regional Cancer Center Lansing MI
St Francis Hospital & Medical Center Hartford CT
St. Johns Hospital & Medical Center Grosse Pointe Woods MI
St. Joseph Mercy Hospital Ann Arbor MI
St. Joseph Mercy Oakland Pontac MI
St. Mary Mercy Hospital Livonia MI
St. Mary`s Medical Center Saginaw MI
Tallahassee Memorial Hospital Tallahassee FL
University of Texas-MD Anderson Cancer Center Houston TX
Webber Cancer Center Warren MI
Updated: 11/6/2013

You must be logged in to view this file.

Login  |  Close

You must be logged in to view this file.

Login  |  Close